title: Sorafenib for patients with differentiated thyroid cancer--authors' reply.
authors.affiliation: Department of Otorhinolaryngology: Head and Neck Surgery, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: brosem@mail.med.upenn.edu.
authors.forename: Marcia S
authors.initials: MS
authors.lastname: Brose
authors.affiliation: Gustave Roussy, Villejuif, France.
authors.forename: Martin
authors.initials: M
authors.lastname: Schlumberger
authors.affiliation: Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.
authors.forename: Carol
authors.initials: C
authors.lastname: Peña
authors.affiliation: Bayer Pharma AG, Berlin, Germany.
authors.forename: Christian
authors.initials: C
authors.lastname: Kappeler
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D013964:Thyroid Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide